NCT06079879: An ongoing trial by Merck Sharp & Dohme LLC
This trial is ongoing. It must report results 2 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06079879 |
|---|---|
| Title | A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 31, 2023 |
| Completion date | July 30, 2027 |
| Required reporting date | July 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |